| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
|
Nature
|
2012
|
11.91
|
|
2
|
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
|
Nature
|
2011
|
3.22
|
|
3
|
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
|
Proc Natl Acad Sci U S A
|
2012
|
1.51
|
|
4
|
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.
|
Blood
|
2011
|
1.44
|
|
5
|
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
|
J Pathol
|
2012
|
1.42
|
|
6
|
Simultaneous structural variation discovery among multiple paired-end sequenced genomes.
|
Genome Res
|
2011
|
1.39
|
|
7
|
Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations.
|
Blood
|
2010
|
1.36
|
|
8
|
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.
|
J Pathol
|
2012
|
1.07
|
|
9
|
Poly-gene fusion transcripts and chromothripsis in prostate cancer.
|
Genes Chromosomes Cancer
|
2012
|
1.05
|
|
10
|
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.
|
Genome Biol
|
2014
|
1.04
|
|
11
|
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
|
J Med Chem
|
2008
|
0.90
|
|
12
|
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
|
Bioorg Med Chem Lett
|
2006
|
0.86
|
|
13
|
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
0.78
|
|
14
|
The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.
|
Bioorg Med Chem Lett
|
2007
|
0.77
|
|
15
|
Development of novel benzotriazines for drug discovery.
|
Expert Opin Drug Discov
|
2008
|
0.76
|
|
16
|
Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
|
Drug Metab Dispos
|
2007
|
0.75
|
|
17
|
An overview and evaluation of combining an addiction liaison nurse outpatient service with hepatitis C outpatient clinics in Glasgow, Scotland.
|
Gastroenterol Nurs
|
2013
|
0.75
|
|
18
|
An alcohol withdrawal tool for use in hospitals.
|
Nurs Times
|
2012
|
0.75
|